Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Phase 2

• Conditions: Hepatocellular Carcinoma (HCC)
• Interventions: Procedure: transarterial chemoembolization (TACE); Biological: Expanded Activated Lymphocytes (EAL)

• Registration Number: NCT05213637
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection.

Detailed Description

HCC, accounting for 80% of all liver cancers, is the third most common cause of cancer-related death worldwide. Radical resection is considered as a curative strategy for patients with primary HCC. However, over 50% of patients experience recurrence after resection, resulting in a very low 5-year survival rate. EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood. This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection. Patients will be randomized in a 1:1 ratio to receive either 20 doses of EAL (1×10\^9\~2×10\^10 per dose) infusion in combination of a single TACE or a single TACE only. Primary endpoint is the independent review committee-determined recurrence-free survival (from randomization to first recurrence or death from any cause). Secondary endpoints include overall survival, cancer-specific survival, adverse events and others.

Study Timeline

• Study Start: 2018-04-25
• Study First Submitted: 2022-01-27
• Study First Submitted QC: 2022-01-27
• Study First Posted: 2022-01-28
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-04
• Last Update Posted: 2022-02-07
• Primary Completion: 2022-06-30
• Study Completion: 2023-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 430

Inclusion Criteria

1. Patients with Stage Ia~IIIa primary HCC with high recurrence risk (defined as single tumor ≥5cm in diameter, or single tumor <5cm in diameter with MVI, PVTT, hepatic vein invasion, satellite lesions or AFP ≥400ng/mL, or multiple tumors).
2. Patients who have undergone a radical resection.
3. ECOG PS Score 0~2.
4. Child-Pugh Score ≤ 7.
5. Patients with adequate hematologic and end-organ function.
6. HBV-HCC and HCV-HCC patients with active viral infection may receive antiviral treatment simultaneously.
7. Patients who have a life expectancy of at least 6 months.

Exclusion Criteria

1. Patients with a history of immune deficiency or autoimmune diseases (such as rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.).
2. Patients with a history of other malignant tumors in the past 5 years.
3. Patients who received chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, and hormone therapy within 1 month prior to screening.
4. Patients who have received microwave ablation, cryotherapy, high-power ultrasound focused ablation and other local ablation methods for liver tumors.
5. Patients with postoperative organ dysfunction or heart and lung diseases.
6. Patients allergic to albumin or with serious allergy history or mental disease.
7. Pregnant or lactating women.
8. Anticipated other clinical trials within 4 weeks before this trial.
9. Patients with HIV or Treponema pallidum infection, septicemia and other uncontrolled infection.
10. Patients after organ or bone marrow transplant.
11. Patients with drug or alcohol abuse/addiction.
12. Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group	transarterial chemoembolization (TACE)	The patients with primary HCC will receive a single TACE after radical resection.
EAL Treatment Group	Expanded Activated Lymphocytes (EAL)	The patients with primary HCC will receive 12\~20 doses of EAL infusion (1×10\^9\~2×10\^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.
EAL Treatment Group	transarterial chemoembolization (TACE)	The patients with primary HCC will receive 12\~20 doses of EAL infusion (1×10\^9\~2×10\^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.

Primary Outcome Measures

Name	Time	Method
Recurrence-free survival (RFS)	6 years	The time from randomization to first documented of disease recurrence determined by IRC or death from any cause (whichever occurs first).

Secondary Outcome Measures

Name	Time	Method
Cancer-specific survival (CSS)	6 years	The time from randomization to death from HCC.
Adverse events (AE)	6 years	Percentage of participants with adverse events.
Overall survival (OS)	6 years	The time from randomization to death from any cause.

Trial Locations

Locations (1)

Chinese PLA General Hospital; 🇨🇳 Beijing, Beijing, China